Logo image of DWTX

DOGWOOD THERAPEUTICS INC (DWTX) Stock Fundamental Analysis

NASDAQ:DWTX - Nasdaq - US92829J2033 - Common Stock - Currency: USD

5.33  -0.14 (-2.56%)

Fundamental Rating

3

DWTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. While DWTX has a great health rating, there are worries on its profitability. DWTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

DWTX had negative earnings in the past year.
In the past year DWTX has reported a negative cash flow from operations.
DWTX had negative earnings in each of the past 5 years.
In the past 5 years DWTX always reported negative operating cash flow.
DWTX Yearly Net Income VS EBIT VS OCF VS FCFDWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

DWTX has a Return On Assets of -15.66%. This is amongst the best in the industry. DWTX outperforms 81.11% of its industry peers.
DWTX's Return On Equity of -22.98% is amongst the best of the industry. DWTX outperforms 83.60% of its industry peers.
Industry RankSector Rank
ROA -15.66%
ROE -22.98%
ROIC N/A
ROA(3y)-95.71%
ROA(5y)-84.23%
ROE(3y)-108.75%
ROE(5y)-94.18%
ROIC(3y)N/A
ROIC(5y)N/A
DWTX Yearly ROA, ROE, ROICDWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

DWTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DWTX Yearly Profit, Operating, Gross MarginsDWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, DWTX has more shares outstanding
The number of shares outstanding for DWTX has been reduced compared to 5 years ago.
There is no outstanding debt for DWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DWTX Yearly Shares OutstandingDWTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
DWTX Yearly Total Debt VS Total AssetsDWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.21, we must say that DWTX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DWTX (-1.21) is comparable to the rest of the industry.
There is no outstanding debt for DWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACCN/A
DWTX Yearly LT Debt VS Equity VS FCFDWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

DWTX has a Current Ratio of 5.21. This indicates that DWTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of DWTX (5.21) is comparable to the rest of the industry.
DWTX has a Quick Ratio of 5.21. This indicates that DWTX is financially healthy and has no problem in meeting its short term obligations.
DWTX has a Quick ratio (5.21) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.21
Quick Ratio 5.21
DWTX Yearly Current Assets VS Current LiabilitesDWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for DWTX have decreased strongly by -97.93% in the last year.
EPS 1Y (TTM)-97.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.70% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.77%
EPS Next 2Y24.44%
EPS Next 3Y17.7%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DWTX Yearly Revenue VS EstimatesDWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 20M 40M 60M 80M 100M
DWTX Yearly EPS VS EstimatesDWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DWTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DWTX Price Earnings VS Forward Price EarningsDWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DWTX Per share dataDWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

DWTX's earnings are expected to grow with 17.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.44%
EPS Next 3Y17.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DWTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DOGWOOD THERAPEUTICS INC

NASDAQ:DWTX (5/21/2025, 1:15:54 PM)

5.33

-0.14 (-2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/dmh
Earnings (Next)08-06 2025-08-06
Inst Owners2.44%
Inst Owner Change166.39%
Ins Owners5.62%
Ins Owner Change0%
Market Cap10.18M
Analysts82.5
Price Target17.34 (225.33%)
Short Float %13.5%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-188.76%
Min EPS beat(2)-306.71%
Max EPS beat(2)-70.8%
EPS beat(4)1
Avg EPS beat(4)-106.62%
Min EPS beat(4)-306.71%
Max EPS beat(4)22.6%
EPS beat(8)4
Avg EPS beat(8)-38.13%
EPS beat(12)8
Avg EPS beat(12)-17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-69.28%
PT rev (3m)-68.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4650%
EPS NY rev (1m)-24.18%
EPS NY rev (3m)-19.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.16
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.36
EYN/A
EPS(NY)-4.93
Fwd EYN/A
FCF(TTM)-4.6
FCFYN/A
OCF(TTM)-4.6
OCFYN/A
SpS0
BVpS33.66
TBVpS-6.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.66%
ROE -22.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.71%
ROA(5y)-84.23%
ROE(3y)-108.75%
ROE(5y)-94.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.21
Quick Ratio 5.21
Altman-Z -1.21
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.43%
EPS Next Y16.77%
EPS Next 2Y24.44%
EPS Next 3Y17.7%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-160.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-80.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.49%
OCF growth 3YN/A
OCF growth 5YN/A